FDA Panel Rejects Sintilimab Clinical Trial Data From China
The new drug for lung cancer had clinical trial data only from China; FDA officials made clear their opposition to using studies conducted in only one nation as a basis for drug approvals.
Medscape Medical News
source https://www.medscape.com/viewarticle/968320?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/968320?src=rss
Comments
Post a Comment